Tonghua Dongbao Pharmaceutical Co Ltd Capital Reinvestment Ratio
Tonghua Dongbao Pharmaceutical Co Ltd capital reinvestment ratio. Tonghua Dongbao Pharmaceutical Co Ltd (600867) has a Capital Reinvestment Ratio of 2.39x as of September 2025, meaning it reinvests 2% of its operating cash flow (CN¥62.99 Million) in capital expenditures (CN¥150.58 Million). Check how aggressively does Tonghua Dongbao Pharmaceutical Co Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Tonghua Dongbao Pharmaceutical Co Ltd (2000–2025)
Capital reinvestment ratio of Tonghua Dongbao Pharmaceutical Co Ltd from 2000 to 2025. This chart tracks Tonghua Dongbao Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 25 annual periods. Also explore 600867 net asset momentum to track the company's year-over-year net asset growth rate.
Tonghua Dongbao Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2000–2025)
Tonghua Dongbao Pharmaceutical Co Ltd capital reinvestment ratio by year from 2000 to 2025. For the full cash flow conversion analysis, see cash flow conversion of Tonghua Dongbao Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.75x | CN¥689.23 Million | CN¥517.69 Million | ▼ -39.3% |
| 2024 | 1.24x | CN¥459.74 Million | CN¥568.73 Million | ▲ +206.1% |
| 2023 | 0.40x | CN¥861.52 Million | CN¥348.13 Million | ▼ -29.1% |
| 2022 | 0.57x | CN¥863.09 Million | CN¥491.63 Million | ▲ +7.6% |
| 2021 | 0.53x | CN¥1.13 Billion | CN¥600.75 Million | ▲ +31.6% |
| 2020 | 0.40x | CN¥1.19 Billion | CN¥479.59 Million | ▲ +58.1% |
| 2019 | 0.25x | CN¥1.15 Billion | CN¥293.13 Million | ▼ -71.1% |
| 2018 | 0.88x | CN¥876.94 Million | CN¥773.07 Million | ▲ +356.8% |
| 2017 | 0.19x | CN¥961.19 Million | CN¥185.50 Million | ▼ -66.0% |
| 2016 | 0.57x | CN¥725.76 Million | CN¥411.53 Million | ▼ -58.3% |
| 2015 | 1.36x | CN¥294.58 Million | CN¥400.09 Million | ▲ +163.6% |
| 2014 | 0.52x | CN¥205.89 Million | CN¥106.08 Million | ▼ -40.2% |
| 2013 | 0.86x | CN¥221.06 Million | CN¥190.36 Million | ▼ -30.8% |
| 2012 | 1.24x | CN¥194.32 Million | CN¥241.83 Million | ▲ +174.7% |
| 2010 | 0.45x | CN¥160.40 Million | CN¥72.66 Million | ▼ -4.8% |
| 2009 | 0.48x | CN¥166.20 Million | CN¥79.07 Million | ▼ -22.5% |
| 2008 | 0.61x | CN¥92.31 Million | CN¥56.67 Million | ▼ -71.3% |
| 2007 | 2.14x | CN¥120.94 Million | CN¥258.34 Million | ▲ +17.6% |
| 2006 | 1.82x | CN¥158.00 Million | CN¥286.90 Million | ▲ +40.3% |
| 2005 | 1.29x | CN¥92.23 Million | CN¥119.38 Million | ▼ -65.3% |
| 2004 | 3.73x | CN¥13.17 Million | CN¥49.08 Million | ▲ +193.0% |
| 2003 | 1.27x | CN¥45.51 Million | CN¥57.90 Million | ▼ -54.5% |
| 2002 | 2.79x | CN¥31.99 Million | CN¥89.41 Million | ▲ +270.9% |
| 2001 | 0.75x | CN¥117.73 Million | CN¥88.69 Million | ▼ -58.2% |
| 2000 | 1.80x | CN¥29.12 Million | CN¥52.46 Million | — |